Kayla Kjelshus
Nurse Practitioner · Merriam, KSNPI 1225499031
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,779 of the $7,163 with a category attached, or 80.7%. AbbVie accounts for 88.9% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $6,917, more than ten times the $165 reported in 2023. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $86.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Upsher-smith Laboratories LLC$165
- Lundbeck LLC$106
- Mallinckrodt Hospital Products Inc.$69
- Teva Pharmaceuticals USA, Inc.$63
- Axsome Therapeutics, Inc.$57
- plus $335 from 12 others
What the payments were for
- Speaking & faculty fees$5,77981%
- Food & beverage$1,38419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $6,369 |
| Upsher-smith Laboratories LLC | 3 | $165 |
| Lundbeck LLC | 5 | $106 |
| Mallinckrodt Hospital Products Inc. | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Eisai Inc. | 2 | $50 |
| Genentech USA, Inc. | 2 | $50 |
| UCB, Inc. | 2 | $35 |
| Neurelis, Inc. | 1 | $31 |
| Catalyst Pharmaceuticals, Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Biogen | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$5,025
- QULIPTA$754
- ZEMBRACE SYMTOUCH$105
- TOSYMRA$105
How this compares
$7,163 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 201 | $172,928 |
| UbrelvyUbrogepant | 106 | $154,145 |
| Aimovig AutoinjectorErenumab-Aooe | 159 | $151,896 |
| Nurtec OdtRimegepant Sulfate | 58 | $84,555 |
| QuliptaAtogepant | 46 | $60,104 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 45 | $39,729 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $10,556 |
| Sumatriptan Succinate | 261 | $9,794 |
| Naratriptan Hcl | 31 | $2,986 |
| RizatriptanRizatriptan Benzoate | 142 | $2,780 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $2,320 |
| Nortriptyline Hcl | 104 | $2,231 |
| Zonisamide | 79 | $1,713 |
| Topiramate | 96 | $1,663 |
| Amitriptyline Hcl | 54 | $1,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $6,369 | $214,249152 claims |
| PfizerNurtec Odt | $17 | $84,55558 claims |
| Upsher-smith Laboratories LLCTopiramate | $165 | $1,66396 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Merriam
- Monica ThielenMerriam$5K
- Gary GrafTopeka$726K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
- Catherine PowellWichita$50K
- Lori RanalloWestwood$48K
- Kristyn MilburnPleasanton$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.